PSTV — Plus Therapeutics, Inc.

Summary of Plus Therapeutics Q4 2024 Earnings Call

1. Key Financial Results and Metrics

• Cash and Investments: $3.6 million as of December 31, 2024, down from $8.6 million in 2023.
• Grant Revenue: Increased to $5.8 million in 2024 from $4.9 million in 2023. Expected grant revenue for 2025 is projected between $6 million and $8 million.
• Operating Loss: Total operating loss for 2024 was $14.7 million, compared to $13.3 million in 2023.
• Net Loss: Reported at $13 million or $1.95 per share, an improvement from a net loss of $13.3 million or $4.24 per share in 2023.

2. Strategic Updates and Business Highlights

• Equity Financing: Completed a $15 million underwritten equity financing, regaining compliance with NASDAQ's minimum stockholder equity requirement.
• Leadership Changes: Strengthened senior leadership with new appointments including Dr. Mike Rosol as Chief Development Officer and Mr. Russ Bradley as President of CNSide.
• Product Development: REYOBIQ, the lead drug, has received FDA orphan designation for leptomeningeal metastasis (LM) due to lung and breast cancer. The drug is in mid-stage clinical trials.
• Clinical Trials: Completed the Phase 1 trial for REYOBIQ, determining a recommended Phase 2 dose and planning for a dose expansion trial. Promising safety and efficacy data were reported.
• CNSide Diagnostics: The CNSide platform is set to launch commercially, enhancing the market for REYOBIQ and addressing diagnostic needs in CNS cancers.

3. Forward Guidance and Outlook

• Clinical Development: Anticipate an FDA meeting to align on the path to approval for REYOBIQ in breast cancer-related LM. Plans to initiate a multiple dose escalation trial for REYOBIQ are also in place.
• CNSide Launch: Expected to fully launch the CNSide tumor cell enumeration test in 2025, with market access activities ongoing.
• Data Presentations: Key data presentations planned at major oncology conferences in 2025, including the Nuclear Medicine and Neuro-Oncology Symposium in May.

4. Bad News, Challenges, or Points of Concern

• Cash Position: The significant decrease in cash reserves raises concerns about liquidity and operational sustainability without additional funding.
• Operating Losses: Continued increases in operating losses may indicate challenges in managing costs, particularly related to clinical trials.
• Market Competition: The potential for competitive pressures in the CNS diagnostics market could impact CNSide's commercial success.

5. Notable Q&A Insights

• CNSide Commercialization: The company plans to focus on a niche market with academic neuro-oncologists initially, rather than building a large sales force. Future partnerships may be considered.
• GBM Trial Goals: The recurrent GBM trial is on track, with expectations to complete enrollment and achieve data results in 2025. The trial is powered against historical survival rates of around eight months.
• Market Opportunity for CNSide: The potential market for CNSide is estimated at 500,000 tests annually in the U.S., driven by its ability to diagnose and monitor treatment in patients with CNS cancers.

This summary encapsulates the key aspects of Plus Therapeutics' Q4 2024 earnings call, highlighting financial performance, strategic initiatives, future outlook, and areas of concern.